BS_K2VYFVKZ
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 67.24704336399473
- age_years
- 2.181
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.578
- IL6_JAK_STAT3_SIGNALING+0.561
- INTERFERON_GAMMA_RESPONSE+0.541
- ALLOGRAFT_REJECTION+0.473
- MYOGENESIS+0.429
- CHOLESTEROL_HOMEOSTASIS+0.419
- COMPLEMENT+0.398
- INFLAMMATORY_RESPONSE+0.387
- COAGULATION+0.373
- TNFA_SIGNALING_VIA_NFKB+0.366
Top 10 suppressed
- MYC_TARGETS_V1-0.326
- E2F_TARGETS-0.242
- PANCREAS_BETA_CELLS-0.199
- SPERMATOGENESIS-0.176
- G2M_CHECKPOINT-0.140
- PROTEIN_SECRETION-0.060
- DNA_REPAIR-0.040
- HEME_METABOLISM-0.019
- ANDROGEN_RESPONSE+0.007
- UV_RESPONSE_UP+0.007
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_JH29M4KG | pilocytic astrocytoma | — | 0.942 |
| 2 | BS_24AHZ9ZW | low-grade glioma | — | 0.900 |
| 3 | BS_WG203ECV | pilocytic astrocytoma | — | 0.897 |
| 4 | BS_MF9X3PKH | low-grade glioma | — | 0.896 |
| 5 | BS_V89HGTET | pilocytic astrocytoma | — | 0.895 |
| 6 | BS_77CDMEY4 | Ganglioglioma | — | 0.894 |
| 7 | BS_HC5M8JTC | low-grade glioma | — | 0.892 |
| 8 | BS_S7CZY2CH | low-grade glioma | — | 0.891 |
| 9 | BS_EFEZB0ZH | low-grade glioma | — | 0.890 |
| 10 | BS_NB5XWMJT | low-grade glioma | — | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.578 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.561 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.541 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.473 | Idelalisib | — uncovered |
| MYOGENESIS | 0.429 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.419 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.398 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.387 | Idelalisib | — uncovered |
| COAGULATION | 0.373 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.366 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.355 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.346 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.346 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.333 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.323 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.307 | Inavolisib | — uncovered |
| APOPTOSIS | 0.299 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.279 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.274 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.268 | Temsirolimus | — uncovered |